• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血干细胞移植后造血干细胞功能不良的挽救:代表法语国家骨髓移植和细胞治疗学会(SFGM-TC)的一项多中心回顾性研究。

Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

机构信息

Department of Pediatric Hematology Oncology, University Hospital of Nancy, Nancy, France.

Department of Pediatric Intensive Care, University Hospital of Nancy, Nancy, France.

出版信息

Br J Haematol. 2023 Jun;201(6):1153-1158. doi: 10.1111/bjh.18744. Epub 2023 Mar 27.

DOI:10.1111/bjh.18744
PMID:36974355
Abstract

Haematopoietic stem cell reinjection may be a curative option for poor graft function after haematopoietic stem cell transplantation; however, literature supporting its use remains limited. We conducted a multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, including 55 patients. We demonstrated response rates of nearly 40% and two-year survival of more than 60% in the context of an otherwise deadly complication and we observed that the timing of injection and the degree of cytopenia are strongly associated with outcomes. This study shows the feasibility of the procedure informing on its epidemiology, outcomes and prognostic factors, setting the stage for future guidelines.

摘要

造血干细胞再输注可能是造血干细胞移植后造血功能不良的一种治疗选择;然而,支持其使用的文献仍然有限。我们代表法语骨髓移植和细胞治疗学会进行了一项多中心回顾性研究,共纳入 55 例患者。我们证明,在这种情况下,死亡率极高的严重并发症中,反应率接近 40%,两年生存率超过 60%,并且我们观察到注射时机和血细胞减少程度与结果密切相关。该研究表明了该程序的可行性,为其流行病学、结果和预后因素提供了信息,为未来的指南奠定了基础。

相似文献

1
Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).造血干细胞移植后造血干细胞功能不良的挽救:代表法语国家骨髓移植和细胞治疗学会(SFGM-TC)的一项多中心回顾性研究。
Br J Haematol. 2023 Jun;201(6):1153-1158. doi: 10.1111/bjh.18744. Epub 2023 Mar 27.
2
[Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].[异基因造血干细胞移植受者的疫苗接种:法语国家骨髓移植与细胞治疗协会(SFGM-TC)指南]
Bull Cancer. 2024 Feb;111(2S):S40-S49. doi: 10.1016/j.bulcan.2023.05.007. Epub 2023 Jul 19.
3
[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].[第二次异基因造血干细胞移植:法语国家骨髓移植与细胞治疗协会(SFGM-TC)指南]
Bull Cancer. 2019 Jan;106(1S):S40-S51. doi: 10.1016/j.bulcan.2018.05.018. Epub 2018 Nov 6.
4
[Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis].[多发性硬化症自体造血干细胞移植的适应症及随访:法语国家骨髓移植与细胞治疗协会(SFGM-TC)与法语国家多发性硬化症协会联合发布的指南]
Bull Cancer. 2019 Jan;106(1S):S92-S101. doi: 10.1016/j.bulcan.2018.11.002. Epub 2018 Dec 5.
5
[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].[在淋巴肿瘤中使用替代供体进行异基因造血细胞移植:法语国家骨髓移植和细胞治疗协会(SFGM-TC)指南]
Bull Cancer. 2017 Dec;104(12S):S106-S111. doi: 10.1016/j.bulcan.2017.08.008. Epub 2017 Nov 21.
6
[Graft reinjection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].[移植物再注入:法语国家骨髓移植与细胞治疗协会(SFGM-TC)指南]
Bull Cancer. 2019 Jan;106(1S):S83-S91. doi: 10.1016/j.bulcan.2018.11.001. Epub 2018 Dec 7.
7
[Secondary cancers following allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].[异基因造血干细胞移植后的继发性癌症:法语国家骨髓移植与细胞治疗协会(SFGM-TC)指南]
Bull Cancer. 2024 Feb;111(2S):S22-S28. doi: 10.1016/j.bulcan.2023.02.016. Epub 2023 Mar 13.
8
[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Bull Cancer. 2017 Dec;104(12S):S131-S135. doi: 10.1016/j.bulcan.2017.10.018. Epub 2017 Nov 22.
9
Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).法国自体造血干细胞移植(AHSCT)治疗成人自身免疫性疾病患者:法国骨髓移植和细胞治疗学会(SFGM-TC)的长期结果分析。
Clin Rheumatol. 2019 May;38(5):1501-1511. doi: 10.1007/s10067-019-04435-2. Epub 2019 Jan 21.
10
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.异基因造血干细胞移植后 CD34 选择干细胞增强治疗移植物功能不良的结局:系统评价和荟萃分析。
Transplant Cell Ther. 2021 Oct;27(10):877.e1-877.e8. doi: 10.1016/j.jtct.2021.07.012. Epub 2021 Jul 18.

引用本文的文献

1
The economic cost of care in poor graft function following allogeneic stem cell transplantation.异基因干细胞移植后移植物功能不良的护理经济成本。
Bone Marrow Transplant. 2025 Jan;60(1):97-99. doi: 10.1038/s41409-024-02452-7. Epub 2024 Oct 24.
2
[Selected donor CD34(+) cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis: 3 cases report].[选择供体CD34(+)细胞增强剂用于原发性骨髓纤维化异基因造血干细胞移植后移植物功能不良的挽救治疗:3例报告]
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):785-788. doi: 10.3760/cma.j.cn121090-20240117-00029.
3
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival.
在进行 CD34+ 选择干细胞增强时存在活动性感染与治疗失败和总体生存不良相关。
Blood Adv. 2024 Sep 10;8(17):4729-4737. doi: 10.1182/bloodadvances.2023012418.